Showing results (41-50 of 50) with videos related to
Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Journal of Medicinal Chemistry|November 15, 2008
Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptaseZachary K Sweeney, Seth F Harris, Seth F Arora, et al.Mbio|August 29, 2024
Discovery of GuaB inhibitors with efficacy against <i>Acinetobacter baumannii</i> infectionEric M Kofoed, Ignacio Aliagas, Terry Crawford, et al.Journal of Medicinal Chemistry|November 8, 2013
Discovery of N-[4-[6-tert-butyl-5-methoxy-8-(6-methoxy-2-oxo-1H-pyridin-3-yl)-3-quinolyl]phenyl]methanesulfonamide (RG7109), a potent inhibitor of the hepatitis C virus NS5B polymeraseFrancisco X Talamas, Sarah C Abbot, Shalini Anand, et al.Bioorganic & Medicinal Chemistry Letters|August 28, 2009
Non-nucleoside inhibitors of HCV polymerase NS5B. Part 4: structure-based design, synthesis, and biological evaluation of benzo[d]isothiazole-1,1-dioxidesJavier de Vicente, Robert T Hendricks, David B Smith, et al.Journal of Medicinal Chemistry|December 21, 2013
Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitorsAnthony A Estrada, Bryan K Chan, Charles Baker-Glenn, et al.Bioorganic & Medicinal Chemistry Letters|August 25, 2009
Non-nucleoside inhibitors of HCV polymerase NS5B. Part 3: synthesis and optimization studies of benzothiazine-substituted tetramic acidsJavier de Vicente, Robert T Hendricks, David B Smith, et al.Bioorganic & Medicinal Chemistry Letters|November 13, 2024
Discovery of potent dihydro-oxazinoquinolinone inhibitors of GuaB for the treatment of tuberculosisYuebiao Zhou, Ignacio Aliagas, Shumei Wang, et al.Bioorganic & Medicinal Chemistry Letters|May 22, 2009
Non-nucleoside inhibitors of HCV polymerase NS5B. Part 2: Synthesis and structure-activity relationships of benzothiazine-substituted quinolinedionesJavier de Vicente, Robert T Hendricks, David B Smith, et al.Journal of Medicinal Chemistry|September 19, 2012
Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitorsAnthony A Estrada, Xingrong Liu, Charles Baker-Glenn, et al.Structure (London, England : 1993)|April 7, 2016
Outcome of the First wwPDB/CCDC/D3R Ligand Validation WorkshopPaul D Adams, Kathleen Aertgeerts, Cary Bauer, et al.Pageof 5